Overview

Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety profile of alfimeprase as assessed by monitoring of adverse events, serious adverse events and major bleeding events for up to 120 minutes following the instillation of study drug to an occluded central venous access device.
Phase:
Phase 3
Details
Lead Sponsor:
ARCA Biopharma, Inc.